UK Biobank moved to metered cloud-only access in 2023-24, ~doubling project costs

UK Biobank — a UK research charity serving over 30,000 approved researchers worldwide — transitioned during 2023 and 2024 from bulk data download to a cloud-only research platform metered per-analysis, on top of an existing £9,000 three-year access fee (S-0042). Members of the neuroscience community publicly reported that their research project costs would approximately double under the new model.

The case illustrates that "access" is a graduated property, not binary. UK Biobank did not shut down; it did not block any approved researcher. It changed the operational model under which the data is accessible, in a direction that imposes substantial new continuing costs on every research project that uses the platform. For underfunded labs, the new costs are equivalent to access loss.

This is C-0020's affordability variant: the platform persists, the access mechanism persists, but the cost structure changes on a timeline the research community does not control. The architectural response is not "negotiate harder with UK Biobank" — UK Biobank's cost transition reflects real operational economics of cloud compute. The architectural response is to maintain off-platform copies of relevant slices when permitted, and to architect research workflows so that no single platform's pricing change can double project costs without alternatives.

UK Biobank specifically permits export under approved terms; the operational question is whether downstream researchers exercise that permission as a standard practice or only after the cost shift forces them to.